Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses a five-year analysis of the MURANO study (NCT02005471) which compared fixed-duration venetoclax plus rituximab therapy with bendamustine plus rituximab therapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Five-year follow-up data found sustained progression-free survival (PFS) and overall survival (OS) with venetoclax plus rituximab. Undetectable minimal residual disease (uMRD) at the end of treatment was associated with improved OS in the venetoclax-rituximab cohort. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Dr Arnon Kater, MD, PhD, has received research funding from BMS, Roche/Genentech, Johnson & Johnson and AbbVie; has received speakers fees from AbbVie; and is a member of advisory boards for Roche/Genentech, Johnson & Johnson and AbbVie.